The four-plates test-retest paradigm to discriminate anxiolytic effects

Psychopharmacology (Berl). 2005 Jun;180(1):73-83. doi: 10.1007/s00213-004-2130-1. Epub 2005 Jan 26.

Abstract

Rationale: Animal models of anxiety such as the four-plates test (FPT) enable the detection of an anxiolytic effect not only of benzodiazepines (BZDs) but also of other non-BZD anxiolytic compounds such as the antidepressants paroxetine and venlafaxine. Retesting mice in animal models of anxiety markedly alters the behavioural profile of various drugs.

Objectives: The aim of this study was first to investigate the function of GABA(A)/BZD receptor and passive avoidance acquisition in the FPT "test-retest". The second aim of this study was to evaluate the capacity of the FPT to discriminate BZDs from other non-BZD anxiolytics in experienced mice.

Methods: The FPT was performed in naive and experienced mice (submitted to the test 24 h previously). The drugs studied were two BZDs, diazepam (1 mg/kg) and alprazolam (0.25 mg/kg); flumazenil, a GABA(A) receptor antagonist (8 mg/kg); atropine sulphate, a muscarinic cholinergic receptor antagonist (4 mg/kg) known for its amnesic properties; paroxetine, a selective serotonin reuptake inhibitor (4 and 8 mg/kg); venlafaxine, a serotonin and noradrenalin reuptake inhibitor (4 and 16 mg/kg); and DOI, a 5-HT2A agonist (1 mg/kg).

Results: Our results reveal an increase of anxiety (decrease of punished passages) in saline-experienced mice. Diazepam, alprazolam, paroxetine and venlafaxine did not prevent the increase in anxiety during retest, revealing a passive avoidance acquisition. Flumazenil did not modify the anxiogenic-like behaviour of experienced mice. In contrast, atropine seems to oppose the increase of anxiety; however, its effect is weak and disputable. DOI was the only anxiolytic compound able to oppose the decrease of punished passages of experienced mice.

Conclusion: Anxiogenic behaviour on retesting indicates aversive learning. The protocol test-retest is unable to discriminate between the anxiolytic effect of BZDs from that of paroxetine or venlafaxine. However, this modified model may constitute a new tool to investigate other neural pathways implicated in anxiety.

Publication types

  • Comparative Study

MeSH terms

  • Adrenergic Uptake Inhibitors / pharmacology
  • Amphetamines / pharmacology
  • Animals
  • Anti-Anxiety Agents / pharmacology*
  • Anxiety / drug therapy
  • Anxiety / psychology
  • Atropine / pharmacology
  • Avoidance Learning / drug effects
  • Behavior, Animal / drug effects
  • Benzodiazepines / pharmacology*
  • Cholinergic Agents / pharmacology
  • Cyclohexanols / pharmacology
  • Discrimination, Psychological*
  • Dose-Response Relationship, Drug
  • Male
  • Mice
  • Paroxetine / pharmacology
  • Receptors, GABA-A / drug effects*
  • Receptors, GABA-A / physiology
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Serotonin 5-HT2 Receptor Agonists
  • Venlafaxine Hydrochloride

Substances

  • Adrenergic Uptake Inhibitors
  • Amphetamines
  • Anti-Anxiety Agents
  • Cholinergic Agents
  • Cyclohexanols
  • Receptors, GABA-A
  • Serotonin 5-HT2 Receptor Agonists
  • Serotonin Uptake Inhibitors
  • Benzodiazepines
  • Paroxetine
  • Atropine
  • Venlafaxine Hydrochloride
  • 4-iodo-2,5-dimethoxyphenylisopropylamine